To foster accountability for external assets, Ipsen integrates its innovation and scouting teams directly into the R&D organization, rather than siloing them with business development. This ensures partnered programs have a natural home and are not seen as competition to internal efforts, preventing cultural friction.

BridgeBio's unique structure creates dedicated subsidiaries for each program. This empowers small, focused teams closest to the science to make key decisions—"play calling on the field"—without layers of bureaucracy. This model dramatically accelerates development, leading to unprecedented output of new drugs.

Platform-based biotech companies need a new generalist role that combines deep scientific knowledge with product creativity and business development skills. These individuals create multiple 'front doors' for partners but are hard to find in a field historically dominated by specialists.

To prevent losing top scientific talent to administrative roles, the "Venture Catalyst" model pairs a scientist-founder with a dedicated business team. This allows the scientist to remain in the lab, focused on research, while the experienced partners handle finance, legal, and daily management.

Scientists in specialized roles like immunogenicity risk becoming siloed service providers. To maintain impact and growth, they must proactively collaborate with other functions like CMC, safety, and quality. This provides a holistic view of drug development and integrates their expertise into the entire process.

The foundation of a successful biotech is scientific innovation. Business leaders who openly respect scientists as the focal point for value creation can build trusting, effective relationships that accelerate development and commercialization.

When building its first commercial team, Ionis CEO Brett Monia, a scientist, prioritized hiring experienced leaders who also appreciated the company's deep-rooted scientific culture. This focus on cultural alignment was critical to successfully integrating the new commercial function into the R&D-centric organization.

Siphoning off cutting-edge work to a separate 'labs' group demotivates core teams and disconnects innovation from those who own the customer. Instead, foster 'innovating teams' by making innovation the responsibility of the core product teams themselves.

To launch new products and compete with agile startups, embed a small "incubation seller" team directly within the technology organization. This model ensures tight alignment between product, engineering, and the first revenue-generating efforts, mirroring the cross-functional approach of an early-stage company.